CA-CIRCLECI
14.3.2024 14:01:34 CET | Business Wire | Press release
CircleCI, the leading continuous integration and continuous delivery (CI/CD) platform, today unveiled CircleCI releases, which enables developers to automate the release orchestration process directly from the CircleCI UI. With current support for Kubernetes and Amazon SageMaker, developers now have end-to-end visibility of their deployments in production and access to rollback commands (e.g., restore version, scale component, and restart component) for seamless release management. CircleCI releases makes deploying code less risky, user-focused, and more accessible for developers to ship faster with confidence.
Today, developers operate in increasingly complex tech stacks yet are under pressure to move quickly without compromising software quality. As a result, elite engineering teams are incorporating agile development practices like progressive delivery and canary releases, which provide the guardrails necessary for risk-free deployments via the ability to target, segment, and roll back releases. CircleCI releases enables software teams to automate the progressive delivery process with support for Argo Rollouts, giving developers complete control over their releases. Future support for blue-green deployments is slated for later in 2024. By automating CI/CD pipelines directly into the release orchestration process, software teams dramatically reduce mean-time-to-recovery (MTTR), giving them the confidence to resolve issues should releases go awry with little to no impact on their customers.
Key features and benefits of CircleCI releases include:
- Change validation: Developers can validate the entire change from build to production.
- User-focused releases and minimized risk: Developers can connect their CI/CD pipeline directly to the customer experience to make releases user-focused, risk-free, and rollback-friendly.
- Increased code confidence: With automated release orchestration, teams will definitively know that their code is working as intended.
- Automated rollbacks: Manual rollbacks take 45 minutes to an hour. Automated rollbacks make the delivery process fast, efficient, and streamlined.
- Real-time service validation: Developers can safely release code to a controlled subset of real users in a live production environment to get immediate feedback on how code performs. Flexible subsets include internal testers, beta customers, or an external low-risk customer group of choice.
- Performance degradation prevention: Automate your release conditions and best practices into a release policy to act as guardrails. By automating software validation in production and rolling back releases when necessary, developers, operators, and customers are protected from performance degradation.
“If you look at every other deploy and release vendor on the market, they’re built to service centralized release and operations teams who want tighter control over deploys,” said Rob Zuber, CTO of CircleCI. “But this doesn’t reflect the reality of elite software teams who depend on developers to drive and deliver fast innovation. Our approach to CircleCI releases provides a developer-centric workflow that enables them to ship faster and monitor new features in production coupled with the safety net of quickly rolling back releases if something goes wrong.”
CircleCI releases is now available to all CircleCI users. To learn more or chat about how CircleCI can empower your team to deliver innovation faster, visit one of our experts at KubeCon EU, booth M16 from March 19-21, 2024. Get started using CircleCI releases today.
About CircleCI
CircleCI is a leading continuous integration and continuous delivery (CI/CD) platform, enabling more than two million global users on elite engineering teams like Okta, Hinge, and Hugging Face to rapidly build, test, deploy, and monitor software they can trust. Through powerful pipeline automation, CircleCI manages limitless complexity at scale through unmatched flexibility and reliability, reducing the time from build to delivery by 3x the industry average. For more information about CircleCI, visit www.circleci.com or follow us on Twitter, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314509917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom